Approach to the patient with rheumatoid arthritis.

A. T. Slotkoff, P. Katz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

RA remains a therapeutic challenge. Despite substantial data from therapeutic trials, the precise therapy of this often debilitating disease remains controversial. A variety of agents are available to the clinician for the treatment of this disease, yet the precise timing of their use and the determination of situations in which efficacy is most likely to be observed is still unclear. However, it is obvious that earlier intervention and more aggressive forms of therapy are currently advocated by most rheumatologists. Given the rapidity with which this disease can induce substantial morbidity, the use of second-line agents early in the course of this process is warranted. Whether or not combination therapy provides any benefit is still unproved. As our understanding of the pathogenic mechanisms involved in the development of RA evolve, and with the development of newer immunomodulatory agents, it is likely that more specific forms of therapy can be developed. It is hoped that these protocols will permit more precise treatment of the abnormalities leading to this disease without global suppression of the immune system or other unacceptable side effects.

Original languageEnglish
Pages (from-to)197-240
Number of pages44
JournalAdvances in Internal Medicine
Volume39
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Therapeutics
Immune System
Morbidity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Approach to the patient with rheumatoid arthritis. / Slotkoff, A. T.; Katz, P.

In: Advances in Internal Medicine, Vol. 39, 01.01.1994, p. 197-240.

Research output: Contribution to journalArticle

Slotkoff, AT & Katz, P 1994, 'Approach to the patient with rheumatoid arthritis.', Advances in Internal Medicine, vol. 39, pp. 197-240.
Slotkoff, A. T. ; Katz, P. / Approach to the patient with rheumatoid arthritis. In: Advances in Internal Medicine. 1994 ; Vol. 39. pp. 197-240.
@article{5232f4deaf864a97b5c8ba6a644ade6f,
title = "Approach to the patient with rheumatoid arthritis.",
abstract = "RA remains a therapeutic challenge. Despite substantial data from therapeutic trials, the precise therapy of this often debilitating disease remains controversial. A variety of agents are available to the clinician for the treatment of this disease, yet the precise timing of their use and the determination of situations in which efficacy is most likely to be observed is still unclear. However, it is obvious that earlier intervention and more aggressive forms of therapy are currently advocated by most rheumatologists. Given the rapidity with which this disease can induce substantial morbidity, the use of second-line agents early in the course of this process is warranted. Whether or not combination therapy provides any benefit is still unproved. As our understanding of the pathogenic mechanisms involved in the development of RA evolve, and with the development of newer immunomodulatory agents, it is likely that more specific forms of therapy can be developed. It is hoped that these protocols will permit more precise treatment of the abnormalities leading to this disease without global suppression of the immune system or other unacceptable side effects.",
author = "Slotkoff, {A. T.} and P. Katz",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "39",
pages = "197--240",
journal = "Advances in Internal Medicine",
issn = "0065-2822",
publisher = "Year Book Medical Publishers",

}

TY - JOUR

T1 - Approach to the patient with rheumatoid arthritis.

AU - Slotkoff, A. T.

AU - Katz, P.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - RA remains a therapeutic challenge. Despite substantial data from therapeutic trials, the precise therapy of this often debilitating disease remains controversial. A variety of agents are available to the clinician for the treatment of this disease, yet the precise timing of their use and the determination of situations in which efficacy is most likely to be observed is still unclear. However, it is obvious that earlier intervention and more aggressive forms of therapy are currently advocated by most rheumatologists. Given the rapidity with which this disease can induce substantial morbidity, the use of second-line agents early in the course of this process is warranted. Whether or not combination therapy provides any benefit is still unproved. As our understanding of the pathogenic mechanisms involved in the development of RA evolve, and with the development of newer immunomodulatory agents, it is likely that more specific forms of therapy can be developed. It is hoped that these protocols will permit more precise treatment of the abnormalities leading to this disease without global suppression of the immune system or other unacceptable side effects.

AB - RA remains a therapeutic challenge. Despite substantial data from therapeutic trials, the precise therapy of this often debilitating disease remains controversial. A variety of agents are available to the clinician for the treatment of this disease, yet the precise timing of their use and the determination of situations in which efficacy is most likely to be observed is still unclear. However, it is obvious that earlier intervention and more aggressive forms of therapy are currently advocated by most rheumatologists. Given the rapidity with which this disease can induce substantial morbidity, the use of second-line agents early in the course of this process is warranted. Whether or not combination therapy provides any benefit is still unproved. As our understanding of the pathogenic mechanisms involved in the development of RA evolve, and with the development of newer immunomodulatory agents, it is likely that more specific forms of therapy can be developed. It is hoped that these protocols will permit more precise treatment of the abnormalities leading to this disease without global suppression of the immune system or other unacceptable side effects.

UR - http://www.scopus.com/inward/record.url?scp=0028320519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028320519&partnerID=8YFLogxK

M3 - Article

C2 - 7908157

AN - SCOPUS:0028320519

VL - 39

SP - 197

EP - 240

JO - Advances in Internal Medicine

JF - Advances in Internal Medicine

SN - 0065-2822

ER -